Abstract: The present disclosure addresses this need by providing crystalline fine particle forms of PRX-3140 potassium salt, methods for preparation and the treatment for Alzheimer's disease (AD) and other dementias affecting the cholinergic and/or serotonergic systems including post-traumatic stress disorder (PTSD). In certain aspects, the present disclosure provides novel methods of preparing the compound of Formula I thereof, or PRX-3140 potassium salts, crystalline fine particle forms of PRX-3140 potassium salt, and compositions comprising them. In certain aspects, the present disclosure provides novel crystalline fine particle form of PRX-3140 potassium salt which may provide advantages including improved bioavailability and stability relative to other crystalline or amorphous forms. In other aspects, the present disclosure provides oral dosage forms of crystalline fine particle form of PRX-3140 potassium salt and excipients with improved stability.

Abstract: The present disclosure addresses this need by providing crystalline fine particle forms of PRX-3140 potassium salt, methods for preparation and the treatment for Alzheimer's disease (AD) and other dementias affecting the cholinergic and/or serotonergic systems including post-traumatic stress disorder (PTSD). In certain aspects, the present disclosure provides novel methods of preparing the compound of Formula I thereof, or PRX-3140 potassium salts, crystalline fine particle forms of PRX-3140 potassium salt, and compositions comprising them. In certain aspects, the present disclosure provides novel crystalline fine particle form of PRX-3140 potassium salt which may provide advantages including improved bioavailability and stability relative to other crystalline or amorphous forms. In other aspects, the present disclosure provides oral dosage forms of crystalline fine particle form of PRX-3140 potassium salt and excipients with improved stability.

Abstract: The present disclosure addresses this need by providing crystalline fine particle forms of PRX-3140 potassium salt, methods for preparation and the treatment for Alzheimer's disease (AD) and other dementias affecting the cholinergic and/or serotonergic systems including post-traumatic stress disorder (PTSD). In certain aspects, the present disclosure provides novel methods of preparing the compound of Formula I thereof, or PRX-3140 potassium salts, crystalline fine particle forms of PRX-3140 potassium salt, and compositions comprising them. In certain aspects, the present disclosure provides novel crystalline fine particle form of PRX-3140 potassium salt which may provide advantages including improved bioavailability and stability relative to other crystalline or amorphous forms. In other aspects, the present disclosure provides oral dosage forms of crystalline fine particle form of PRX-3140 potassium salt and excipients with improved stability.

Abstract: The present invention relates to an aqueous hydrogel composition for topical application to skin or a wound, comprising doxycycline with carboxy-methyl-cellulose, glycerol, citric acid, and at least one pH stabilizer, wherein the composition includes a suspension or dispersion of particles of doxycycline chelated with calcium, said particles have an average diameter less than or equal to about 100 microns, wherein the doxycycline chelated with calcium is present in an amount ranging from greater than about 0.1 weight % to about 3 weight %, wherein the composition includes less than 0.5 weight % 4-epidoxycycline. The present invention also describes methods for making a composition for topical applications as well as methods of treating skin or a wound with an aqueous hydrogel composition comprising doxycycline with carboxy-methyl-cellulose, glycerol, citric acid, and at least one pH stabilizer.

Abstract: The present invention relates to an aqueous hydrogel composition for topical application to skin or a wound, comprising doxycycline with carboxy-methyl-cellulose, glycerol, citric acid, and at least one pH stabilizer, wherein the composition includes a suspension or dispersion of particles of doxycycline chelated with calcium, said particles have an average diameter less than or equal to about 100 microns, wherein the doxycycline chelated with calcium is present in an amount ranging from greater than about 0.1 weight % to about 3 weight %, wherein the composition includes less than 0.5 weight % 4-epidoxycycline. The present invention also describes methods for making a composition for topical applications as well as methods of treating skin or a wound with an aqueous hydrogel composition comprising doxycycline with carboxy-methyl-cellulose, glycerol, citric acid, and at least one pH stabilizer.

Abstract: The present invention relates to an aqueous hydrogel composition for topical application to skin or a wound, comprising doxycycline with carboxy-methyl-cellulose, glycerol, citric acid, and at least one pH stabilizer, wherein the composition includes a suspension or dispersion of particles of doxycycline chelated with calcium, said particles have an average diameter less than or equal to about 100 microns, wherein the doxycycline chelated with calcium is present in an amount ranging from greater than about 0.1 weight % to about 3 weight %, wherein the composition includes less than 0.5 weight % 4-epidoxycycline. The present invention also describes methods for making a composition for topical applications as well as methods of treating skin or a wound with an aqueous hydrogel composition comprising doxycycline with carboxy-methyl-cellulose, glycerol, citric acid, and at least one pH stabilizer.

Abstract: The present invention relates to an aqueous hydrogel composition for topical application to skin or a wound, comprising doxycycline with carboxy-methyl-cellulose, glycerol, citric acid, and at least one pH stabilizer, wherein the composition includes a suspension or dispersion of particles of doxycycline chelated with calcium, said particles have an average diameter less than or equal to about 100 microns, wherein the doxycycline chelated with calcium is present in an amount ranging from greater than about 0.1 weight % to about 3 weight %, wherein the composition includes less than 0.5 weight % 4-epidoxycycline. The present invention also describes methods for making a composition for topical applications as well as methods of treating skin or a wound with an aqueous hydrogel composition comprising doxycycline with carboxy-methyl-cellulose, glycerol, citric acid, and at least one pH stabilizer.